Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $19.00 Consensus Target Price from Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been given a consensus rating of “Moderate Buy” by the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $19.00.

A number of equities research analysts recently commented on LXEO shares. Guggenheim began coverage on shares of Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Raymond James Financial started coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price target on the stock. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 13th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in Lexeo Therapeutics by 69.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares during the period. CWM LLC raised its stake in shares of Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after purchasing an additional 6,216 shares during the period. Ethic Inc. bought a new stake in shares of Lexeo Therapeutics during the 2nd quarter valued at $44,000. Cerity Partners LLC purchased a new stake in Lexeo Therapeutics during the 2nd quarter worth about $50,000. Finally, Intech Investment Management LLC boosted its stake in Lexeo Therapeutics by 20.7% in the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after purchasing an additional 2,342 shares during the period. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Trading Down 1.3%

LXEO stock opened at $7.44 on Thursday. The stock has a market cap of $543.05 million, a P/E ratio of -2.76 and a beta of 1.75. The stock’s fifty day simple moving average is $9.15 and its two-hundred day simple moving average is $7.34. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. As a group, analysts forecast that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.